Potent inhibition of human influenza H5N1 virus by oligonucleotides derived by SELEX

Cheng, Congsheng; Dong, Jing; Yao, Lihong; Chen, Aijun; Jia, Runqing; Huan, Lifang; Guo, Jianqiu; Shu, Yuelong; Zhang, Zhiqing

doi:10.1016/j.bbrc.2007.11.183

Cited by 85 publications

(57 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such aptamers could be applied for both the diagnostic and the therapy of the viral infection. To create potential antiviral drugs, DNA aptamers against the globular H9 HA domain (subtype H9N2) (Choi et al, 2011) and DNA and RNA aptamers against the receptor binding region HA1 of HA (subtype Н5N1) (Cheng et al, 2008; Kwon et al, 2014; Park et al, 2011) were selected. All these aptamers possessed antiviral properties and significantly inhibited the viral infection in cell cultures.…”

Section: Antiviral Aptamersmentioning

confidence: 99%

Aptamers against pathogenic microorganisms

Davydova

Vorobjeva

Pyshnyi

et al. 2015

Critical Reviews in Microbiology

View full text Add to dashboard Cite

An important current issue of modern molecular medicine and biotechnology is the search for new approaches to early diagnostic assays and adequate therapy of infectious diseases. One of the promising solutions to this problem might be a development of nucleic acid aptamers capable of interacting specifically with bacteria, protozoa, and viruses. Such aptamers can be used for the specific recognition of infectious agents as well as for blocking of their functions. The present review summarizes various modern SELEX techniques used in this field, and of several currently identified aptamers against viral particles and unicellular organisms, and their applications. The prospects of applying nucleic acid aptamers for the development of novel detection systems and antibacterial and antiviral drugs are discussed.

show abstract

Section: Antiviral Aptamersmentioning

confidence: 99%

Aptamers against pathogenic microorganisms

Davydova

Vorobjeva

Pyshnyi

et al. 2015

Critical Reviews in Microbiology

View full text Add to dashboard Cite

show abstract

“…Indeed, small RNA molecules have been proved to be efficient inhibitors targeting functional RNA genomic domains (including those at the 5′-UTR) as well as genetic products of HIV-1101112131415.Some of the inhibitory RNAs have been included in clinical trials for HIV-1 treatment16. This strategy has been also applied to other clinically relevant RNA viruses17181920.…”

mentioning

confidence: 99%

Efficient HIV-1 inhibition by a 16 nt-long RNA aptamer designed by combining in vitro selection and in silico optimisation strategies

Sánchez‐Luque

Stich

Manrubia

et al. 2014

Sci Rep

View full text Add to dashboard Cite

The human immunodeficiency virus type-1 (HIV-1) genome contains multiple, highly conserved structural RNA domains that play key roles in essential viral processes. Interference with the function of these RNA domains either by disrupting their structures or by blocking their interaction with viral or cellular factors may seriously compromise HIV-1 viability. RNA aptamers are amongst the most promising synthetic molecules able to interact with structural domains of viral genomes. However, aptamer shortening up to their minimal active domain is usually necessary for scaling up production, what requires very time-consuming, trial-and-error approaches. Here we report on the in vitro selection of 64 nt-long specific aptamers against the complete 5′-untranslated region of HIV-1 genome, which inhibit more than 75% of HIV-1 production in a human cell line. The analysis of the selected sequences and structures allowed for the identification of a highly conserved 16 nt-long stem-loop motif containing a common 8 nt-long apical loop. Based on this result, an in silico designed 16 nt-long RNA aptamer, termed RNApt16, was synthesized, with sequence 5′-CCCCGGCAAGGAGGGG-3′. The HIV-1 inhibition efficiency of such an aptamer was close to 85%, thus constituting the shortest RNA molecule so far described that efficiently interferes with HIV-1 replication.

show abstract

“…Resent years, aptamers have been thought to be representing alternative options to antibodies for diagnostics development (Cunningham et al, 2005;Yoshida et al, 2009 and. Recently, various anti-influenza virus protein aptamers have been developed (Cheng et al, 2008;Gopinath et al, 2006;Jeon et al, 2004;. These aptamers showed relatively strict specificity for the influenza virus with broad subtype specificities such as H5N1, H1N1, and H3N2 (Yoshida et al, 2009;Shiratori et al, 2014).…”

Section: Introductionmentioning

confidence: 96%